The vision of SLC is to be a world leader in the development and design of kinase targeted therapies with the aim to deliver better patient outcomes. We are a privately owned company headquartered in Vancouver, Canada.
SLC has received a ruling from the Investment Capital Branch of the British Columbia Ministry of Small Business and Economic Development confirming that we are eligible to receive investments from Venture Capital Corporations (“VCC”) registered under the Small Business Venture Capital Act (British Columbia) (the “SBVCA”) and that we have been registered as an Eligible Small Business Corporation (“EBC”) under section 28.2 of the SBVCA.
For information regarding our company, its products or investment opportunities in SLC, please contact
110-13120 Vanier Place